Core Viewpoint - The report highlights the current premium rates of AH shares, with Northeast Electric (00042), Zhejiang Shibao (01057), and Sinopec Oilfield Service (01033) leading in premium rates, while CATL (03750), China Merchants Bank (03968), and Hansoh Pharmaceutical (01276) are at the bottom of the list [1]. Premium Rate Rankings - The top three AH shares by premium rate are: - Northeast Electric (00042) with a premium rate of 815.25% - Zhejiang Shibao (01057) with a premium rate of 354.93% - Sinopec Oilfield Service (01033) with a premium rate of 295.40% [1]. - The bottom three AH shares by premium rate are: - CATL (03750) with a premium rate of -11.82% - China Merchants Bank (03968) with a premium rate of -2.30% - Hansoh Pharmaceutical (01276) with a premium rate of 1.62% [1]. Deviation Values - The top three shares with the highest deviation values are: - Goldwind Technology (02208) with a deviation value of 21.73% - Jinyu Group (02009) with a deviation value of 19.04% - Sinopec Oilfield Service (01033) with a deviation value of 18.76% [1]. - The bottom three shares with the lowest deviation values are: - Zhejiang Shibao (01057) with a deviation value of -41.23% - Junda Co., Ltd. (02865) with a deviation value of -39.46% - Yangtze Optical Fibre and Cable (06869) with a deviation value of -26.61% [1]. Additional Insights - The report includes a detailed table of the top and bottom AH shares by premium rate and deviation value, providing a comprehensive overview of the current market situation [2].

Core Viewpoint - Heng Rui Medicine (01276) has seen its stock price increase by over 3%, currently trading at HKD 68.75 with a transaction volume of HKD 71.27 million, following the acceptance of two drug application submissions by the National Medical Products Administration (NMPA) [1][1]. Group 1: Drug Application Acceptance - The company's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received an acceptance notice from the NMPA for the drug application of HR20013, an injectable formulation of Phosphorlorapitant Palonosetron, aimed at preventing nausea and vomiting induced by moderately emetogenic chemotherapy [1][1]. - The application for HR20013 is based on a multicenter, randomized, double-blind, positive-controlled Phase III clinical trial (HR20013-302) evaluating its efficacy and safety [1][1]. Group 2: Innovative Drug Submission - Heng Rui Medicine and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., also received an acceptance notice from the NMPA for a new indication of the innovative drug, injectable Camrelizumab, in combination with Apatinib Mesylate tablets [1][1]. - This application is based on a randomized controlled, open-label, multicenter Phase III clinical trial (SHR-1210-III-336 study) comparing the efficacy and safety of Camrelizumab and Apatinib combined with TACE versus TACE alone in patients with unresectable hepatocellular carcinoma [1][1].

每经AI快讯，恒瑞医药(01276.HK)涨超3%，截至发稿，涨3%，报68.75港元，成交额7126.63万港元。 ...

Core Viewpoint - Heng Rui Medicine (600276) has seen its stock price increase by over 3%, currently trading at 68.75 HKD with a transaction volume of 71.27 million HKD, following the acceptance of two drug application submissions by the National Medical Products Administration (NMPA) [1] Group 1: Drug Approvals - The company's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received an acceptance notice from the NMPA for the marketing authorization application of HR20013, an injectable drug for preventing nausea and vomiting caused by moderately emetogenic anticancer drugs, based on a Phase III clinical trial [1] - Heng Rui Medicine and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., also received an acceptance notice for the marketing authorization application of a new indication for the innovative drug SHR-1210 (injectable carrelizumab) in combination with apatinib, based on a Phase III clinical trial comparing the efficacy and safety of the combination treatment against TACE alone for patients with unresectable hepatocellular carcinoma [1]

Core Viewpoint - Heng Rui Medicine (01276) has seen its stock price increase by over 3%, currently trading at HKD 68.75, with a transaction volume of HKD 71.27 million [1] Group 1: Regulatory Approvals - The company's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration (NMPA) for the marketing authorization application of HR20013, an injectable drug for preventing nausea and vomiting caused by moderately emetogenic anticancer drugs [1] - The application for HR20013 is based on a multicenter, randomized, double-blind, positive-controlled Phase III clinical trial (HR20013-302) evaluating its efficacy and safety [1] Group 2: New Indications for Existing Drugs - Heng Rui Medicine and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., have also received a "Notice of Acceptance" from the NMPA for the marketing authorization application of a new indication for the innovative drug, SHR-1210 (injectable carrelizumab) in combination with apatinib mesylate tablets [1] - This application is based on a randomized controlled, open-label, multicenter Phase III clinical trial (SHR-1210-III-336 study) comparing the efficacy and safety of carrelizumab and apatinib combined with TACE versus TACE alone in patients with unresectable hepatocellular carcinoma [1]

智通财经APP讯，恒瑞医药(01276)发布公告，于2026年2月4日，该公司斥资931.7万元回购16.5万股A 股。 ...

恒瑞医药(01276.HK)2月4日耗资931.7万元回购16.5万股A股 恒瑞医药(01276.HK)：福建盛迪医药"注射 用磷罗拉匹坦帕洛诺司琼"药品上市许可申请获受理 相关事件 格隆汇2月4日丨恒瑞医药(01276.HK)发布公告，2026年2月4日耗资人民币931.70万元回购16.5万股A 股，回购价格每股56.25-57.09元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2026年2月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前 ...

Group 1 - The core viewpoint of the news is that 恒瑞医药's stock has experienced a decline, with a 2.00% drop on February 4, 2023, and a year-to-date decrease of 5.46% [1] - As of February 4, 2023, 恒瑞医药's stock price was reported at 56.32 yuan per share, with a total market capitalization of 373.07 billion yuan [1] - The company has seen a net outflow of 1.57 billion yuan in principal funds, with significant selling pressure observed [1] Group 2 - 恒瑞医药, established on April 28, 1997, and listed on October 18, 2000, is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology [2] - The company's revenue composition includes 86.88% from product sales, 12.63% from licensing income, and 0.49% from other sources [2] - As of September 30, 2025, 恒瑞医药 reported a total of 397,300 shareholders, with an average of 16,058 circulating shares per shareholder [3] Group 3 - For the period from January to September 2025, 恒瑞医药 achieved a revenue of 23.188 billion yuan, representing a year-on-year growth of 14.85%, and a net profit of 5.751 billion yuan, up 24.50% year-on-year [3] - The company has distributed a total of 9.303 billion yuan in dividends since its A-share listing, with 3.568 billion yuan distributed in the last three years [4] - As of September 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited and China Securities Finance Corporation, with notable changes in shareholding [4]